Syndax Pharmaceuticals
SNDX
17.03
-0.34
-1.96%
Syndax Pharmaceuticals
US · SNDX
#2947 by market cap
Listed 2016
17.03
-0.34
-1.96%
Live - 5344 symbols - heartbeat 96s ago
· 2026-10-08 07:42
Pre-market
16.80
-1.35%
After-hours
17.20
+1.00%
- Market cap
- 1.52B
- P/E (TTM)i
- -6.78
- P/Bi
- 100.77
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 32%
Reader sentiment
Are you bullish or bearish on SNDX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Buy
Avg price target
37.33 +119.2%
Price target rangecurrent 17.03
Low26.00
Avg37.33
High57.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | H.C. Wainwright | -- | BUY | 38.00 |
| 2026-09-29 | Citi | -- | BUY | 57.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 38.00 |
| 2026-08-21 | UBS | -- | BUY | 33.00 |
| 2026-08-14 | Stifel | -- | BUY | 40.00 |
| 2026-08-11 | J.P. Morgan | -- | BUY | 40.00 |
| 2026-08-06 | Stifel | -- | BUY | 40.00 |
| 2026-08-05 | BofA Securities | -- | BUY | 26.00 |
| 2026-08-05 | Citi | -- | BUY | 57.00 |
| 2026-08-05 | H.C. Wainwright | -- | BUY | 38.00 |
| 2026-08-05 | Barclays | -- | BUY | 37.00 |
| 2026-08-04 | TD Cowen | -- | BUY | -- |
| 2026-07-22 | BofA Securities | -- | BUY | 29.00 |
| 2026-07-20 | Barclays | -- | BUY | 37.00 |
| 2026-07-15 | TD Cowen | -- | BUY | -- |
| 2026-07-15 | BofA Securities | -- | BUY | 29.00 |
| 2026-07-15 | Stifel | -- | BUY | 46.00 |
| 2026-07-15 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-07-15 | Barclays | -- | BUY | 37.00 |
| 2026-07-14 | Citi | -- | BUY | 57.00 |
| 2026-07-14 | Goldman Sachs | -- | BUY | 34.00 |
| 2026-07-14 | Guggenheim | -- | BUY | 31.00 |
| 2026-06-15 | Stifel | -- | BUY | 46.00 |
| 2026-06-15 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-06-12 | Guggenheim | -- | BUY | 31.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | After close | ±8.43% | +4.40% (in line) |
| 2026/Q1 | 2026-04-30 | After close | ±12.87% | -10.83% (in line) |
| 2025/Q4 | 2026-02-26 | After close | ±15.45% | +5.03% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±12.79% | +11.56% (in line) |
| 2025/Q2 | 2025-08-04 | After close | ±13.97% | +21.10% (beat) |
| 2025/Q1 | 2025-05-05 | After close | ±20.27% | -21.59% (beat) |
| 2024/Q4 | 2025-03-03 | -- | ±17.49% | -1.02% (in line) |
| 2024/Q3 | 2024-11-05 | After close | ±17.32% | +8.43% (in line) |
| 2024/Q2 | 2024-08-01 | After close | ±13.06% | -4.36% (in line) |
| 2024/Q1 | 2024-05-08 | -- | ±9.21% | -3.45% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±16.39% | -2.17% (in line) |
| 2023/Q3 | 2023-11-02 | After close | ±16.41% | +0.14% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:42:13 · For reference only, not investment advice and not tailored to your situation.